

MARC research papers.

1. Hou R, Beardmore R, Holmes C, Osmond C, Darekar A. A case-control study of the locus coeruleus degeneration in Alzheimer's disease. *European Neuropsychopharmacology*. 2021;43:153-9.
2. Femminella GD, Livingston NR, Raza S, Van Der Doef T, Frangou E, Love S, et al. Does insulin resistance influence neurodegeneration in non-diabetic Alzheimer's subjects? *Alzheimer's research & therapy*. 2021;13(1):1-11.
3. Zafeiridi E, McMichael A, Mirakhur A, McHenry M, Holmes C, McGuinness B. Are tumour necrosis factor inhibitor drugs associated with a lower risk of dementia? *International journal of geriatric psychiatry*. 2020;35(7):802-3.
4. Sussams R, Schlotz W, Clough Z, Amin J, Simpson S, Abbott A, et al. Psychological stress, cognitive decline and the development of dementia in amnesic mild cognitive impairment. *Scientific reports*. 2020;10(1):1-11.
5. McGrattan A, Mcevoy CT, Woodside JV, Linden G, Passmore AP, Holmes C, et al. Adherence to a Mediterranean diet is associated with better cognitive performance many years later in the PRIME cohort: Prevention (nonpharmacological)/Nutrition. *Alzheimer's & Dementia*. 2020;16:e045069.
6. McDowell B, Holmes C, Edwards C, Cardwell C, McHenry M, Meenagh G, et al. Mild cognitive impairment and rheumatoid arthritis: *Neuropsychiatry and behavioral neurology/Mild cognitive impairment/Early symptomatic disease*. *Alzheimer's & Dementia*. 2020;16:e042837.
7. Iles A, He PJ, Katis IN, Galanis P, Kumar AJ, Teeling JL, et al., editors. Laser-patterned lateral-flow devices with multiple flow-paths for semi-quantitative measurement of the inflammatory biomarker, C-reactive protein (Conference Presentation). *Microfluidics, BioMEMS, and Medical Microsystems XVIII*; 2020: International Society for Optics and Photonics.
8. Holstege H, Hulsman M, Charbonnier C, Grenier-Boley B, Quenez O, Grozeva D, et al. Exome sequencing identifies novel AD-associated genes. *medRxiv*. 2020.
9. Gerhard A, Jacobs AH, Goerttler T, Sharples R, Beardmore RC, McDonald KR, et al. A double-blind, placebo-controlled study of the effect of a TNF α inhibitor, Etanercept, on microglial activation in amyloid PET-positive patients with mild cognitive impairment due to AD-intermediate likelihood: Human/Human trials: *Inflammation*. *Alzheimer's & Dementia*. 2020;16:e040331.
10. Femminella GD, van der Doef T, Carver S, Holmes C, Ritchie CW, Lawrence RM, et al. Behavioural symptoms in Alzheimer's disease are associated with white matter lesions (WML) volume and are independent of atrophy and hypometabolism: *Neuroimaging/Optimal neuroimaging measures for tracking disease progression*. *Alzheimer's & Dementia*. 2020;16:e045223.
11. Femminella GD, Frangou E, Love SB, Busza G, Holmes C, Ritchie C, et al. Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study)(vol 20, 191, 2019). *TRIALS*. 2020;21(1).
12. Edwards C, McDowell B, Holroyd C, Cardwell C, McHenry M, Meenagh G, et al. THU0134 COGNITIVE IMPAIRMENT IN RHEUMATOID ARTHRITIS. *BMJ Publishing Group Ltd*; 2020.
13. Edison P, Raza S, Femminella GD, Blunt EG, Carver S, Livingston NR, et al. Relationship between spectral analysis, SUV and SUV Pons ratio as a measure of cerebral

- glucose metabolic rate in Alzheimer's disease: Neuroimaging/multi-modal comparisons. *Alzheimer's & Dementia*. 2020;16:e046068.
14. Edison P, Femminella GD, Nowell J, Raza S, Livingston NR, Blunt EG, et al. Assessing the relationship between cognitive dysfunction and brain atrophy in Alzheimer's disease: Neuroimaging/multi-modal comparisons. *Alzheimer's & Dementia*. 2020;16:e046004.
 15. Edison P, Femminella GD, Livingston NR, Raza S, Nowell J, Carver S, et al. Influence of cerebral glucose metabolic rate on cognitive function in Alzheimer's subjects: Neuroimaging/multi-modal comparisons. *Alzheimer's & Dementia*. 2020;16:e045899.
 16. Bellenguez C, Küçükali F, Jansen I, Andrade V, Moreno-Grau S, Amin N, et al. New insights on the genetic etiology of Alzheimer's and related dementia. medRxiv. 2020.
 17. Bellenguez C, Küçükali F, Jansen I, Andrade V, Morenau-Grau S, Amin N, et al. Large meta-analysis of genome-wide association studies expands knowledge of the genetic etiology of Alzheimer's disease and highlights potential translational opportunities. MedRxiv. 2020.
 18. Beardmore RC, Darekar A, Holmes C, Boche D, Nicoll JA, Durkin M, et al. Using the Locus Coeruleus as a biomarker in Alzheimer's disease: Neuroimaging/Optimal neuroimaging measures for early detection. *Alzheimer's & Dementia*. 2020;16:e040229.
 19. Beardmore R, Boche D, Darekar A, Durkin M, Holmes C, Hou R, editors. The locus coeruleus in Alzheimer's disease: A potential biomarker. *NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY*; 2020: WILEY 111 RIVER ST, HOBOKEN 07030-5774, NJ USA.
 20. Amin J, Holmes C, Dorey RB, Tommasino E, Casal YR, Williams DM, et al. Neuroinflammation in dementia with Lewy bodies: a human post-mortem study. *Translational psychiatry*. 2020;10(1):1-11.
 21. Amin J, Holmes C, Boche D, Teeling J, Williams A. Cerebral and systemic inflammation in Dementia with Lewy bodies and Alzheimer's disease. 2020.
 22. Amin J, Boche D, Clough Z, Teeling J, Williams A, Gao Y, et al. Peripheral immunophenotype in dementia with Lewy bodies and Alzheimer's disease: an observational clinical study. *Journal of Neurology, Neurosurgery & Psychiatry*. 2020;91(11):1219-26.
 23. Rakic S, Holmes C, Love S, Stewart W, Nicoll JA, Boche D, editors. Effects of systemic infection on the brain in the late stage of Alzheimer's disease. *BRAIN PATHOLOGY*; 2019: WILEY 111 RIVER ST, HOBOKEN 07030-5774, NJ USA.
 24. Nicoll JA, Buckland GR, Harrison CH, Page A, Harris S, Love S, et al. Persistent neuropathological effects 14 years following amyloid- β immunization in Alzheimer's disease. *Brain*. 2019;142(7):2113-26.
 25. Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, et al. Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A β , tau, immunity and lipid processing. *Nature genetics*. 2019;51(3):414-30.
 26. He P, Katis I, Galanis P, Teeling J, Holmes C, Eason R, et al., editors. Multiplexed detection of CRP-SAA1 using laser direct-write-fabricated multiple flow-path lateral flow devices (Conference Presentation). *Microfluidics, BioMEMS, and Medical Microsystems XVII*; 2019: International Society for Optics and Photonics.
 27. He P, Katis I, Galanis P, Teeling J, Holmes C, Eason R, et al., editors. Multiplexed detection of CRP-SAA1 using laser direct-write-fabricated multiple flow-path lateral flow devices 2019: SPIE.
 28. Harrison CH, Sakai K, Johnston DA, Holmes C, Boche D, Nicoll JA. O3-10-03: THE ROLE OF CAPILLARY ANGIOPATHY AND AQUAPORIN 4 IN ARIA INDUCED BY A β IMMUNIZATION. *Alzheimer's & Dementia*. 2019;15:P909-P.

29. Franco-Bocanegra DK, George B, Lau LC, Holmes C, Nicoll JA, Boche D. Microglial motility in Alzheimer's disease and after A β 42 immunotherapy: a human post-mortem study. *Acta neuropathologica communications*. 2019;7(1):1-11.
30. Femminella GD, van der Doef T, Wang Y-T, Frangou E, Love S, Calsolaro V, et al. P2-358: Insulin Resistance Influences Hippocampal Glucose Metabolism Rather Than Hippocampal Volume In Non-diabetic Alzheimer's Disease Patients. *Alzheimers & dementia*. 2019;15(7S, part 4):P736-P.
31. Femminella GD, Frangou E, Love SB, Busza G, Holmes C, Ritchie C, et al. Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study). *Trials*. 2019;20(1):191.
32. Chaudhury S, Brookes KJ, Patel T, Fallows A, Guetta-Baranes T, Turton JC, et al. Alzheimer's disease polygenic risk score as a predictor of conversion from mild-cognitive impairment. *Translational psychiatry*. 2019;9(1):1-7.
33. Chaudhury S, Brookes KJ, Patel T, Fallows A, Guetta-Baranes T, Turton JC, et al. Correction: Alzheimer's disease polygenic risk score as a predictor of conversion from mild-cognitive impairment. *Translational psychiatry*. 2019;9(1):1-.
34. Bocanegra D, Mcauley C, Gourari Y, Holmes C, Nicoll J, Boche D, editors. Evaluation of microglial morphology in Alzheimer's disease and after amyloid-beta-immunotherapy. *GLIA*; 2019: WILEY 111 RIVER ST, HOBOKEN 07030-5774, NJ USA.
35. Bath PM, Scutt P, Anderson CS, Appleton JP, Berge E, Cala L, et al. Prehospital transdermal glyceryl trinitrate in patients with ultra-acute presumed stroke (RIGHT-2): an ambulance-based, randomised, sham-controlled, blinded, phase 3 trial. *The Lancet*. 2019;393(10175):1009-20.
36. Baker E, Sims R, Leonenko G, Frizzati A, Harwood JC, Grozeva D, et al. Gene-based analysis in HRC imputed genome wide association data identifies three novel genes for Alzheimer's disease. *PloS one*. 2019;14(7):e0218111.
37. Wolk DA, Sadowsky C, Safirstein B, Rinne JO, Duara R, Perry R, et al. Use of flutemetamol f 18-labeled positron emission tomography and other biomarkers to assess risk of clinical progression in patients with amnesic mild cognitive impairment. *JAMA neurology*. 2018;75(9):1114-23.
38. Sassi C, Nalls MA, Ridge PG, Gibbs JR, Lupton MK, Troakes C, et al. Mendelian adult-onset leukodystrophy genes in Alzheimer's disease: critical influence of CSF1R and NOTCH3. *Neurobiology of aging*. 2018;66:179. e17-. e29.
39. Ritchie CW, Russ TC, Banerjee S, Barber B, Boaden A, Fox NC, et al. The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer's disease (vol 9, 85, 2017). *ALZHEIMERS RESEARCH & THERAPY*. 2018;10.
40. Ritchie CW, Russ TC, Banerjee S, Barber B, Boaden A, Fox NC, et al. Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer's disease. *Alzheimer's research & therapy*. 2018;10(1).
41. Rakic S, Hung YM, Smith M, So D, Tayler HM, Varney W, et al. Systemic infection modifies the neuroinflammatory response in late stage Alzheimer's disease. *Acta neuropathologica communications*. 2018;6(1):1-13.
42. Peloso GM, Van Der Lee SJ, Project IGoAs, Sims R, van der Lee S, Naj A, et al. Genetically elevated high-density lipoprotein cholesterol through the cholesteryl ester transfer protein gene does not associate with risk of Alzheimer's disease. *Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring*. 2018;10(1):595-8.

43. Paquet C, Nicoll JA, Love S, Mouton-Liger F, Holmes C, Hugon J, et al. Downregulated apoptosis and autophagy after anti-A β immunotherapy in Alzheimer's disease. *Brain Pathology*. 2018;28(5):603-10.
44. McGuinness B, Holmes C, Mirakhor A, Kearsley-Fleet L, Vieira R, Watson K, et al. The influence of TNF inhibitors on dementia incidence in patients with rheumatoid arthritis; an analysis from the BSRBR-RA. *International journal of geriatric psychiatry*. 2018;33(3):556-8.
45. McDowell B, Holmes C, Edwards C, Cardwell C, McHenry M, Meenagh G, et al. 131TNF Inhibitors for the Prevention of Alzheimer's Disease. *Age and Ageing*. 2018;47(suppl_5).
46. Mason A, Holmes C, Edwards CJ. Inflammation and dementia: Using rheumatoid arthritis as a model to develop treatments? *Autoimmunity reviews*. 2018;17(9):919-25.
47. Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Naj AC, Boland A, et al. Meta-analysis of genetic association with diagnosed Alzheimer's disease identifies novel risk loci and implicates Abeta, Tau, immunity and lipid processing. 2018.
48. Holmes C, Sussams R, Gerhard A, Herholz K, Jacobs AH, Consortium I. F4-06-02: INSIGHTS FROM CLINICAL RESEARCH ON THE TIMING AND TRAJECTORY OF IMMUNE ACTIVATION IN ALZHEIMER'S DISEASE. *Alzheimer's & Dementia*. 2018;14(7S_Part_26):P1391-P.
49. Femminella GD, Fan Z, Frangou E, Love S, Calsolaro V, Holmes C, et al. PERIPHERAL INSULIN RESISTANCE DOES NOT CORRELATE WITH CEREBRAL GLUCOSE METABOLIC RATE IN NON-DIABETIC ALZHEIMER'S PATIENTS. *Alzheimer's & Dementia*. 2018;14(7):P1157-P8.
50. Collaborative E, Blanco-Colino R, Lee S, Kamarajah S, Vasko P, Kuiper S, et al. Body mass index and complications following major gastrointestinal surgery: a prospective, international cohort study and meta-analysis. *Colorectal Disease*. 2018;20(8):O215-O25.
51. Chaudhury S, Patel T, Barber IS, Guetta-Baranes T, Brookes KJ, Chappell S, et al. Polygenic risk score in postmortem diagnosed sporadic early-onset Alzheimer's disease. *Neurobiology of aging*. 2018;62:244. e1-. e8.
52. Webster L, Groskreutz D, Grinbergs-Saull A, Howard R, T O'Brien J, Mountain G, et al. Results of patient and public involvement consultation. Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations. 2017.
53. Webster L, Groskreutz D, Grinbergs-Saull A, Howard R, T O'Brien J, Mountain G, et al. Research question and objectives. Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations: NIHR Journals Library; 2017.
54. Webster L, Groskreutz D, Grinbergs-Saull A, Howard R, T O'Brien J, Mountain G, et al. Consensus conference. Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations: NIHR Journals Library; 2017.
55. Webster L, Groskreutz D, Grinbergs-Saull A, Howard R, T O'Brien J, Mountain G, et al. Results of the systematic review. Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations. 2017.
56. Webster L, Groskreutz D, Grinbergs-Saull A, Howard R, T O'Brien J, Mountain G, et al. Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations. *Health technology assessment (Winchester, England)*. 2017;21(26):1.

57. Webster L, Groskreutz D, Grinbergs-Saull A, Howard R, O'Brien JT, Mountain G, et al. Core outcome measures for interventions to prevent or slow the progress of dementia for people living with mild to moderate dementia: Systematic review and consensus recommendations. *PLoS One*. 2017;12(6):e0179521.
58. Sims R, Van Der Lee SJ, Naj AC, Bellenguez C, Badarinarayan N, Jakobsdottir J, et al. Rare coding variants in *PLCG2*, *ABI3*, and *TREM2* implicate microglial-mediated innate immunity in Alzheimer's disease. *Nature genetics*. 2017;49(9):1373-84.
59. Ritchie CW, Russ TC, Banerjee S, Barber B, Boaden A, Fox NC, et al. The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer's disease. *Alzheimer's research & therapy*. 2017;9(1):1-7.
60. O'Brien JT, Holmes C, Jones M, Jones R, Livingston G, McKeith I, et al. Clinical practice with anti-dementia drugs: a revised (third) consensus statement from the British Association for Psychopharmacology. *Journal of Psychopharmacology*. 2017;31(2):147-68.
61. Knapp M, King D, Romeo R, Adams J, Baldwin A, Ballard C, et al. Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial). *International Journal of Geriatric Psychiatry*. 2017;32(12):1205-16.
62. Hou R, Garner M, Holmes C, Osmond C, Teeling J, Lau L, et al. Peripheral inflammatory cytokines and immune balance in generalised anxiety disorder: case-controlled study. *Brain, behavior, and immunity*. 2017;62:212-8.
63. Holmes C, Sussams R, Schlotz W, Lau L, Clough Z, Amin J, et al. [EC-02-01]: SYSTEMIC INFLAMMATION AND DISEASE PROGRESSION AND DEVELOPMENT OF ALZHEIMER'S DISEASE. *Alzheimer's & Dementia*. 2017;13(7S_Part_11):P546-P.
64. Holmes C, Grothe MJ, Carare RO, Herrup K, M-Y Lee V, Williams J. EMERGING CONCEPTS IN BASIC SCIENCE: PANEL SESSION. *Alzheimer's & Dementia*. 2017;13(7S_Part_25):P1224-P.
65. Holmes C. Inflammation in Alzheimer's disease. *Dementia: CRC Press*; 2017. p. 528-38.
66. Crosby D, Bossutt P, Brockehurst P, Chamberlain C, Dive C, Holmes C, et al. The MRC Framework for the Development, Design and Analysis of Stratified Medicine Research: Enabling Stratified, Precision and Personalised Medicine. 2017.
67. Boche D, Rakic S, Holmes C, Perry H, Stewart W, Love S, et al. [EC-02-02]: THE NEUROINFLAMMATORY PROFILE IN ALZHEIMER'S DISEASE: EFFECT OF SYSTEMIC INFECTION. *Alzheimer's & Dementia*. 2017;13(7S_Part_11):P546-P.
68. Barber IS, Braae A, Clement N, Patel T, Guetta-Baranes T, Brookes K, et al. Mutation analysis of sporadic early-onset Alzheimer's disease using the NeuroX array. *Neurobiology of aging*. 2017;49:215. e1-. e8.
69. Amin J, Williams T, Teeling J, Dorey R, Williams D, Tommasino E, et al. Inflammation in dementia with lewy bodies. *Alzheimer's & Dementia*. 2017;13(7, Supplement):P594-P5.
70. Amin J, Williams T, Teeling J, Dorey R, Williams D, Tommasino E, et al. Central and systemic inflammation in Dementia with Lewy bodies and Alzheimer's disease. *Neuropathology and Applied Neurobiology*. 2017;43(S1):12-3.
71. Vieira R, Watson K, Holmes C, McGuinness B, Hyrich K. 030 The Influence of Tumour Necrosis Factor Inhibitors on Dementia Incidence in Patients with Rheumatoid Arthritis. *RHEUMATOLOGY-LONDON THEN OXFORD-BRITISH SOCIETY FOR RHEUMATOLOGY*. 2016;55(1):i73-i4.
72. Traylor M, Adib-Samii P, Harold D, Alzheimer's Disease Neuroimaging Initiative TISGC, UK Young Lacunar Stroke DNA resource, Dichgans M, Williams J, et al. Shared genetic

contribution to ischemic stroke and Alzheimer's disease. *Annals of neurology*. 2016;79(5):739-47.

73. Sassi C, Nalls MA, Ridge PG, Gibbs JR, Ding J, Lupton MK, et al. ABCA7 p. G215S as potential protective factor for Alzheimer's disease. *Neurobiology of aging*. 2016;46:235. e1-. e9.

74. Rakic S, Hung Y, Wild J, Tayler H, Nicoll J, Holmes C, et al. The effects of acute systemic infection on Alzheimer's disease: O07. *Neuropathology & Applied Neurobiology*. 2016;42:14-5.

75. Nicoll JA, Buckland GR, Harrison CH, Love S, Neal JW, Holmes C, et al. O1-10-02: A 15-Year Neuropathological Follow up Study of the First ab Immunisation Trial (AN1792) in Alzheimer's Disease. *Alzheimer's & Dementia*. 2016;12:P198-P9.

76. Jun G, Ibrahim-Verbaas CA, Vronskaya M, Lambert J-C, Chung J, Naj AC, et al. A novel Alzheimer disease locus located near the gene encoding tau protein. *Molecular psychiatry*. 2016;21(1):108-17.

77. Ide M, Harris M, Stevens A, Sussams R, Hopkins V, Culliford D, et al. Periodontitis and cognitive decline in Alzheimer's disease. *PloS one*. 2016;11(3):e0151081.

78. Hou R, Holmes C, Garner M, Osmond C, Lau L, Baldwin D. Abstract# 1866 How is the immune balance affected in patients with generalised anxiety disorder? *Brain, Behavior, and Immunity*. 2016;57:e43.

79. Hou R, Holmes C, Garner M, Osmond C, Baldwin D. A preliminary investigation of peripheral immune imbalance in generalised anxiety disorder. *European Neuropsychopharmacology*. 2016;2(26):S605.

80. Greenan C, Murphy L, Yu L-M, Kehoe PG, Coulthard E, Bath P, et al. A randomised controlled trial of calcium channel blockade (CCB) with Amlodipine For the treatment of subcortical ischaemic vascular dementia (AFFECT): study protocol. *Trials*. 2016;17(1):1-12.

81. Collaborative S, Drake T, Nepogodiev D, Chapman S, Glasbey J, Khatri C, et al. Multicentre prospective cohort study of body mass index and postoperative complications following gastrointestinal surgery. *The British journal of surgery*. 2016;103(9):1157.

82. Buckland G, Harrison C, Love S, Neal J, Holmes C, Boche D, et al. Topographical distribution of A β removal resulting from A β immunotherapy in Alzheimer's disease: O10. *Neuropathology & Applied Neurobiology*. 2016;42.

83. Boche D, Hung YM, Smith M, Wild J, Tayler H, Nicoll JA, et al. P3-106: Acute Systemic Infection and Fc γ Receptors in Alzheimer's Disease: An Immunosuppressive Environment. *Alzheimer's & Dementia*. 2016;12:P859-P60.

84. Barber IS, García-Cárdenas JM, Sakdapanichkul C, Deacon C, Erazo GZ, Guerreiro R, et al. Screening exons 16 and 17 of the amyloid precursor protein gene in sporadic early-onset Alzheimer's disease. *Neurobiology of aging*. 2016;39:220. e1-. e7.

85. Andreasson KI, Bachstetter AD, Colonna M, Ginhoux F, Holmes C, Lamb B, et al. Targeting innate immunity for neurodegenerative disorders of the central nervous system. *Journal of neurochemistry*. 2016;138(5):653-93.

86. Amin J, Boche D, Holmes C, Williams A, Teeling J, Nicoll J. Central and systemic inflammation in Dementia with Lewy Bodies and Alzheimer's disease. *Neuropathology and Applied Neurobiology*. 2016;42(S1):36-.

87. Tufan AN, Holmes C, Tufan F. Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial. *Neurology*. 2015;85(23):2083-4.

88. Rakic S, Nicoll J, Love S, Holmes C, Perry V, Stewart W, et al. The impact of systemic infection on neuroinflammation in human brain affected by Alzheimer's disease: P05. *Neuropathology & Applied Neurobiology*. 2015;41:32-3.
89. Rakic S, Hung Y, Wild J, Nicoll J, Love S, Holmes C, et al. The effects of systemic infection on neuroinflammation in Alzheimer's disease: T12-39B. *Glia*. 2015;63.
90. Paquet C, Amin J, Mouton-Liger F, Nasser M, Love S, Gray F, et al. Effect of active A β immunotherapy on neurons in human Alzheimer's disease. *The Journal of pathology*. 2015;235(5):721-30.
91. Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, et al. Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses. *The Lancet Neurology*. 2015;14(12):1171-81.
92. Holmes C. ETANERCEPT IN ALZHEIMER DISEASE: A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, PHASE 2 TRIAL Response. *NEUROLOGY*. 2015;85(23):2084-.
93. Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation in Alzheimer's disease. *The Lancet Neurology*. 2015;14(4):388-405.
94. Harris M, Holmes C, Stevens A, Ide M. Periodontal disease, severity and progression of dementia in a residential UK community. *Journal of Clinical Periodontology*. 2015;42(S17):34-5.
95. Escott-Price V, Sims R, Bannister C, Harold D, Vronskaya M, Majounie E, et al. Common polygenic variation enhances risk prediction for Alzheimer's disease. *Brain*. 2015;138(12):3673-84.
96. Curtis C, Gamez JE, Singh U, Sadowsky CH, Villena T, Sabbagh MN, et al. Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. *JAMA neurology*. 2015;72(3):287-94.
97. Consortium IGoAsD, Jones L, Lambert JC, Wang LS, Choi SH, Harold D, et al. Convergent genetic and expression data implicate immunity in Alzheimer's disease. *Alzheimer's & Dementia*. 2015;11(6):658-71.
98. Clough Z, Jeyapaul P, Zotova E, Holmes C. Proinflammatory cytokines and the clinical features of dementia with lewy bodies. *Alzheimer Disease & Associated Disorders*. 2015;29(1):97-9.
99. Butchart J, Brook L, Hopkins V, Teeling J, Püntener U, Culliford D, et al. Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial. *Neurology*. 2015;84(21):2161-8.
100. Amin J, Paquet C, Baker A, Asuni AA, Love S, Holmes C, et al. Effect of amyloid- β (A β) immunization on hyperphosphorylated tau: a potential role for glycogen synthase kinase (GSK)-3 β . *Neuropathology and applied neurobiology*. 2015;41(4):445-57.
101. Sakai K, Boche D, Carare R, Johnston D, Holmes C, Love S, et al. A β immunotherapy for Alzheimer's disease: effects on apoE and cerebral vasculopathy. *Acta neuropathologica*. 2014;128(6):777-89.
102. Perry VH, Holmes C. Microglial priming in neurodegenerative disease. *Nature Reviews Neurology*. 2014;10(4):217-24.
103. Holmes C, Butchart J, Wolfe L, Davies L, Dodge S, Lewsey I, et al. O4-11-02: THE SAFETY AND TOLERABILITY OF ETANERCEPT IN ALZHEIMER'S DISEASE (STEADI-09): A PHASE II DOUBLE BLIND RANDOMISED PLACEBO CONTROLLED TRIAL. *Alzheimer's & Dementia*. 2014;10:P273-P.

104. Holmes C, Butchart J, Wolfe L, Davies L, Dodge S, Lewsey I, et al. THE SAFETY AND TOLERABILITY OF ETANERCEPT IN ALZHEIMER'S DISEASE (STEADI-09): A PHASE II DOUBLE BLIND RANDOMISED PLACEBO CONTROLLED TRIAL. *Alzheimer's & Dementia: The Journal of the Alzheimer's Association*. 2014;4(10):P273.
105. Escott-Price V, Bellenguez C, Wang L-S, Choi S-H, Harold D, Jones L, et al. Gene-wide analysis detects two new susceptibility genes for Alzheimer's disease. *PloS one*. 2014;9(6):e94661.
106. Collaborative S. Impact of postoperative non-steroidal anti-inflammatory drugs on adverse events after gastrointestinal surgery. *Br J Surg*. 2014;101(11):1413-23.
107. Zotova E, Bharambe V, Cheaveau M, Morgan W, Holmes C, Harris S, et al. Inflammatory components in human Alzheimer's disease and after active amyloid- β 42 immunization. *Brain*. 2013;136(9):2677-96.
108. Sussams R, Schlotz W, Perry H, Viv H, Lynn D, Rayner C, et al. P4-191: Systemic inflammatory responses to stress and its impact on cognition in people with mild cognitive impairment. *Alzheimer's & Dementia*. 2013;9:P775-P.
109. Sussams R, Schlotz W, Perry H, Holmes C. 58. Systemic inflammatory responses to stress and its impact on cognition in subjects with Mild Cognitive Impairment. *Brain, Behavior, and Immunity*. 2013;32:e17.
110. Romeo R, Knapp M, Hellier J, Dewey M, Ballard C, Baldwin R, et al. Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. *The British Journal of Psychiatry*. 2013;202(2):121-8.
111. Lambert J-C, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. *Nature genetics*. 2013;45(12):1452-8.
112. Holmes C. Systemic inflammation and Alzheimer's disease. *Neuropathology and applied neurobiology*. 2013;39(1):51-68.
113. Holmes C. Intravenous immunoglobulin for Alzheimer's disease. *The Lancet Neurology*. 2013;3(12):218-9.
114. Dodge S, Rance C, Lim T, Sussams R, Hopkins V, Holmes C. P3-240: Vulnerability to carer burden in the adult offspring carers of people with dementia. *Alzheimer's & Dementia*. 2013;9:P645-P.
115. Butchart J, Wolfe L, Holmes C, Brewer L, Bennett K, Williams D, et al. Psychiatry and mental health. *Age and Ageing*. 2013;42(suppl_3):iii27-iii8.
116. Butchart J, Wolfe L, Holmes C. 6THE SOUTHAMPTON SICKNESS BEHAVIOUR SCALE: VALIDITY, INTERNAL CONSISTENCY AND RELIABILITY IN ALZHEIMER'S DISEASE AND LEWY BODY DEMENTIA. *Age and Ageing*. 2013;42(suppl_2).
117. Butchart J, Wolfe L, Clough Z, Sharif S, Stevens A, Hopkins V, et al. Sickness behaviour in dementia: The Southampton Sickness Behaviour Scale. *Alzheimer's & Dementia*. 2013;4(9):P756.
118. Butchart J, Birch B, Bassily R, Wolfe L, Holmes C. Male sex hormones and systemic inflammation in Alzheimer disease. *Alzheimer Disease & Associated Disorders*. 2013;27(2):153-6.
119. Boche D, Zotova E, Bharambe V, Cheaveau M, Morgan W, Holmes C, et al. P1-344: Characterizing inflammatory components in human Alzheimer's disease and following active beta-amyloid 42 immunization. *Alzheimer's & Dementia*. 2013;9:P283-P4.

120. Boche D, Amin J, Mouton-Liger F, Nasser M, Love S, Gray F, et al. Consequences of beta-amyloid immunotherapy for Alzheimer's disease on neurons in the human cerebral cortex. *Alzheimer's & Dementia*. 2013;9(4S, Part 7):P284.
121. Banerjee S, Hellier J, Romer R, Dewey M, Knapp M, Ballard C, et al. Study of the use of antidepressants for depression in dementia: the HTA-SADD trial—a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine. *Health technology assessment*. 2013;17(7).
122. Banerjee S, Hellier J, Romeo R, Dewey M, Knapp M, Ballard C, et al. Methods. Study of the use of antidepressants for depression in dementia: the HTA-SADD trial—a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine: NIHR Journals Library; 2013.
123. Banerjee S, Hellier J, Romeo R, Dewey M, Knapp M, Ballard C, et al. Project protocol. Study of the use of antidepressants for depression in dementia: the HTA-SADD trial—a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine: NIHR Journals Library; 2013.
124. Zotova E, Bharambe V, Holmes C, Neal J, Love S, Nicoll J, et al. Microglial profile in human Alzheimer's disease following active A β 42 immunization: O24. *Neuropathology & Applied Neurobiology*. 2012;38.
125. Jones L, Holmans P, Hamshere ML, Harold D, Moskvina V, Ivanov D, et al. Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. *PLoS ONE*. 2012;15(11):e13950.
126. Howard R, McShane R, Lindsay J, Ritchie C, Baldwin A, Barber R, et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. *New England Journal of Medicine*. 2012;366(10):893-903.
127. Hollingworth P, Sweet R, Sims R, Harold D, Russo G, Abraham R, et al. Genome-wide association study of Alzheimer's disease with psychotic symptoms. *Molecular psychiatry*. 2012;17(12):1316-27.
128. Gerrish A, Russo G, Richards A, Moskvina V, Ivanov D, Harold D, et al. The role of variation at A β PP, PSEN1, PSEN2, and MAPT in late onset Alzheimer's disease. *Journal of Alzheimer's Disease*. 2012;28(2):377-87.
129. Corbett A, Pickett J, Burns A, Corcoran J, Dunnett SB, Edison P, et al. Drug repositioning for Alzheimer's disease. *Nature Reviews Drug Discovery*. 2012;11(11):833-46.
130. Butchart J, Holmes C. Systemic and central immunity in Alzheimer's disease: therapeutic implications. *CNS neuroscience & therapeutics*. 2012;18(1):64-76.
131. Zotova E, Holmes C, Neal J, Love S, Nicoll J, Boche D. Lower microglial Fc γ RI/II and macrophage scavenger receptor a in human Alzheimer's disease after A β 42 immunisation. *Alzheimer's & Dementia: The Journal of the Alzheimer's Association*. 2011;4(7):S684-S5.
132. Zotova E, Holmes C, Johnston D, Neal JW, Nicoll JA, Boche D. Microglial alterations in human Alzheimer's disease following A β 42 immunization. *Neuropathology and applied neurobiology*. 2011;37(5):513-24.
133. Sims R, Dwyer S, Harold D, Gerrish A, Hollingworth P, Chapman J, et al. No evidence that extended tracts of homozygosity are associated with Alzheimer's disease. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*. 2011;156(7):764-71.
134. Kemp PM, Clyde K, Holmes C. Impact of 123I-FP-CIT (DaTSCAN) SPECT on the diagnosis and management of patients with dementia with Lewy bodies: a retrospective study. *Nuclear medicine communications*. 2011;32(4):298-302.

135. Jones L, Holmans PA, Hamshere ML, Harold D, Moskvina V, Ivanov D, et al. Correction: genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. *PLoS one*. 2011;6(2).
136. Howard R, Phillips P, Johnson T, O'Brien J, Sheehan B, Lindesay J, et al. Determining the minimum clinically important differences for outcomes in the DOMINO trial. *International journal of geriatric psychiatry*. 2011;26(8):812-7.
137. Holmes C, Cunningham C, Zotova E, Culliford D, Perry V. Proinflammatory cytokines, sickness behavior, and Alzheimer disease. *Neurology*. 2011;77(3):212-8.
138. Holmes C, Butchart J. *Systemic inflammation and Alzheimer's disease*. Portland Press Ltd.; 2011.
139. Hollingworth P, Harold D, Sims R, Gerrish A, Lambert J-C, Carrasquillo MM, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. *Nature genetics*. 2011;43(5):429-35.
140. Gerrish A, Russo G, Richards A, Moskvina V, Ivanov D, Harold D, et al. The Role of Variation at APOE, PSEN1, PSEN2, and MAPT in Late Onset Alzheimer's Disease. 1875-8908. 2011.
141. Dodge S, Sussams B, Rance C, Holmes C. An investigation into the prediction of vulnerability to carer burden in adult offspring carers of parents with dementia. *Alzheimer's & Dementia: The Journal of the Alzheimer's Association*. 2011;4(7):S434.
142. Burns A, Perry E, Holmes C, Francis P, Morris J, Howes M-JR, et al. A double-blind placebo-controlled randomized trial of Melissa officinalis oil and donepezil for the treatment of agitation in Alzheimer's disease. *Dementia and geriatric cognitive disorders*. 2011;31(2):158-64.
143. Birch B, Butchart J, Wolfe L, Holmes C. Sex hormones and TNF-alpha in men with Alzheimer's disease. *Alzheimer's & Dementia: The Journal of the Alzheimer's Association*. 2011;4(7):S349.
144. Belbin O, Brown K, Shi H, Medway C, Abraham R, Passmore P, et al. A multi-center study of ACE and the risk of late-onset Alzheimer's disease. *Journal of Alzheimer's Disease*. 2011;24(3):587-97.
145. Banerjee S, Hellier J, Dewey M, Romeo R, Ballard C, Baldwin R, et al. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. *The Lancet*. 2011;378(9789):403-11.
146. Baker A, Holmes C, Love S, Nicoll J, Boche D. Lower glycogen synthase kinase-3 β load in Alzheimer's disease after A β 42 immunisation: P23. *Neuropathology & Applied Neurobiology*. 2011;37.
147. Zotova E, Nicoll JA, Kalaria R, Holmes C, Boche D. Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy. *Alzheimers Res Ther*. 2010;2(1):1-9.
148. Perry VH, Nicoll JA, Holmes C. Microglia in neurodegenerative disease. *Nature Reviews Neurology*. 2010;6(4):193.
149. Nicoll JA, Hawkes C, Holmes C, Weller R, Perry H, Boche D, et al. O3-07-06: Processes underlying the vascular pathophysiology associated with A β immunization in Alzheimer's disease. *Alzheimer's & Dementia*. 2010;6:S143-S.
150. Jones L, Holmans PA, Hamshere ML, Harold D, Moskvina V, Ivanov D, et al. Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. *PLoS one*. 2010;5(11):e13950.
151. Holmes C. *Mental Health: Dementia*. 2010.

152. Elina Z, Clive H, Jim N, James N, Delphine B, editors. Investigation of microglial function following A (beta) 42 immunisation in Alzheimer's disease. *JOURNAL OF NEUROIMMUNOLOGY*; 2010: ELSEVIER SCIENCE BV PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS.
153. Donald J, Holmes C, Neal J, Love S, Zotova E, Nicoll J, et al. Effects of A β 42 immunisation on tau pathology in Alzheimer's disease: P19. *Neuropathology & Applied Neurobiology*. 2010;36:27-8.
154. Delphine B, William M, Clive H, James W, Elina Z, James A, editors. Are vascular inflammatory events responsible for side-effects associated with Abeta immunotherapy in Alzheimer's disease? *JOURNAL OF NEUROIMMUNOLOGY*; 2010: ELSEVIER SCIENCE BV PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS.
155. Carrasquillo MM, Belbin O, Zou F, Allen M, Ertekin-Taner N, Ansari M, et al. Concordant association of insulin degrading enzyme gene (IDE) variants with IDE mRNA, A β , and Alzheimer's disease. *PLoS one*. 2010;5(1):e8764.
156. Boche D, Donald J, Love S, Neal JW, Holmes C, Nicoll J. O3-07-08: A β 42 immunization reduces both tau and A β deposits in Alzheimer's disease. *Alzheimer's & Dementia*. 2010;6:S144-S.
157. Boche D, Donald J, Love S, Harris S, Neal JW, Holmes C, et al. Reduction of aggregated Tau in neuronal processes but not in the cell bodies after A β 42 immunisation in Alzheimer's disease. *Acta neuropathologica*. 2010;120(1):13-20.
158. Boche D, Denham N, Holmes C, Nicoll JA. Neuropathology after active A β 42 immunotherapy: implications for Alzheimer's disease pathogenesis. *Acta neuropathologica*. 2010;120(3):369-84.
159. Van Helmond Z, Boche D, Nicoll J, Holmes C, Neal J, Love S. Oligomeric A β levels following A β 42 immunisation. *Neuropathology & Applied Neurobiology*. 2009;35.
160. Jones R, Sheehan B, Phillips P, Juszczak E, Adams J, Baldwin A, et al. DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease—a multicentre RCT. *Trials*. 2009;10(1):1-11.
161. Huang L, Abuhamdah S, Howes M-JR, Dixon CL, Elliot MS, Ballard C, et al. Pharmacological profile of essential oils derived from *Lavandula angustifolia* and *Melissa officinalis* with anti-agitation properties: focus on ligand-gated channels. *Journal of Pharmacy and Pharmacology*. 2009;61(2):267.
162. Holmes C, Cunningham C, Zotova E, Woolford J, Dean C, Kerr Su, et al. Systemic inflammation and disease progression in Alzheimer disease. *Neurology*. 2009;73(10):768-74.
163. Holmes C, Cotterell D. Role of infection in the pathogenesis of Alzheimer's disease. *CNS drugs*. 2009;23(12):993-1002.
164. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, et al. Genome-wide association study identifies variants at *CLU* and *PICALM* associated with Alzheimer's disease. *Nature genetics*. 2009;41(10):1088-93.
165. Boche D, Zotova E, Holmes C, Neal J, Wilkinson D, Nicoll J. Microglial activation in immunised Alzheimer's disease patients: good or bad? *Neuropathology & Applied Neurobiology*. 2009;35.
166. Belbin O, Carrasquillo M, Zou F, Allen M, Ertekin-Taner N, Brown K, et al. P4-130: Concordant association of functional IDE variant with IDE mRNA, A β , and Alzheimer's disease. *Alzheimer's & Dementia*. 2009;5(4S_Part_15):P469-P70.

167. Ballard C, Brown R, Fossey J, Douglas S, Bradley P, Hancock J, et al. Brief psychosocial therapy for the treatment of agitation in Alzheimer disease (the CALM-AD trial). *The American journal of geriatric psychiatry*. 2009;17(9):726-33.
168. Zotova E, Holmes C, Nicoll J, Boche D. Microglia activation in Alzheimer's disease after Abeta immunization: good or bad? 2008.
169. Williams J, Abraham R, Morgan A, Sims R, Hollingworth P, O'Donovan M, et al. O2-06-01: A powerful, genome-wide association scan for susceptibility genes for late-onset Alzheimer's disease. *Alzheimer's & Dementia*. 2008;4:T143-T.
170. Nicoll J, Boche D, Holmes C. Amyloid- β vaccination for Alzheimer's dementia—Authors' reply. *The Lancet*. 2008;372(9647):1381-2.
171. Narasimhalu K, Lee J, Auchus AP, Chen CP, Wahlin Å, Fahlander K, et al. 日本語目次. *Dementia and Geriatric Cognitive Disorders*. 2008;25.
172. Murdoch N, Morris P, Holmes C. Depression in elderly life sentence prisoners. *International Journal of Geriatric Psychiatry: A journal of the psychiatry of late life and allied sciences*. 2008;23(9):957-62.
173. Morgan K, Carrasquillo M, Belbin O, Brown K, Kalsheker N, Craig D, et al. P3-244: Insulin degrading enzyme and the risk of late-onset Alzheimer's disease: A large replication study in a European population. *Alzheimer's & Dementia*. 2008;4:T592-T.
174. Huang L, Abuhamdah S, Howes MJR, Dixon CL, Elliot MS, Ballard C, et al. Pharmacological profile of essential oils derived from *Lavandula angustifolia* and *Melissa officinalis* with anti-agitation properties: Focus on ligand-gated channels. *Journal of Pharmacy and Pharmacology*. 2008;60(11):1515-22.
175. Howard RJ, Juszczak E, Ballard C, Bentham P, Brown R, Bullock R, et al. Donepezil for the treatment of agitation in Alzheimer's disease. *ACP JOURNAL CLUB*. 2008;148(2):33.
176. Holmes C, Perry H, Cunningham C, Zotova E, Dean C. O3-02-01: Systemic cytokines and clinical progression in Alzheimer's disease. *Alzheimer's & Dementia: The Journal of the Alzheimer's Association*. 2008;4(4):T159-T60.
177. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, et al. Long-term effects of A β 42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. *The Lancet*. 2008;372(9634):216-23.
178. Holmes C. The genetics and molecular biology of dementia. 2008.
179. Holmes C. Causes of dementia. *Medicine*. 2008;9(36):467-70.
180. Brown K, Belbin O, Kalsheker N, Craig D, McGuinness B, Passmore P, et al. P3-207: Angiotensin-converting enzyme and the risk of late-onset Alzheimer's disease. *Alzheimer's & Dementia*. 2008;4:T581-T.
181. Boche D, Zotova E, Weller R, Love S, Neal JW, Pickering R, et al. Consequence of A β immunization on the vasculature of human Alzheimer's disease brain. *Brain*. 2008;131(12):3299-310.
182. Boche D, Zotova E, Holmes C, Nicoll JA. O2-03-05: Microglia and Alzheimer's disease: Implications of A β immunotherapy. *Alzheimer's & Dementia: The Journal of the Alzheimer's Association*. 2008;4(4):T136-T7.
183. Boche D, Holmes C, Wilkinson D, Hopkins V, Bayer A, Jones R, et al. Continued progression of neurodegeneration in Alzheimer's disease despite complete removal of the Abeta plaques? 2008.
184. Bittles AH, Harper S, Anderson E, Prince M, Nagy Z, Hubbard P, et al. Basic science. *Oxford Textbook of Old Age Psychiatry*. 2008.

185. Abuhamdah S, Huang L, Elliott MS, Howes MJR, Ballard C, Holmes C, et al. Pharmacological profile of an essential oil derived from *Melissa officinalis* with anti-agitation properties: Focus on ligand-gated channels. *Journal of Pharmacy and Pharmacology*. 2008;60(3):377-84.
186. Abuhamdah S, Huang L, Elliott M, Howes M, Ballard C, Holmes C. List of references supporting the assessment of *Melissa officinalis* L., folium. channels. 2008;60(3):377-84.
187. Aalten P, Verhey FR, Boziki M, Brugnolo A, Bullock R, Byrne EJ, et al. Consistency of neuropsychiatric syndromes across dementias: results from the European Alzheimer Disease Consortium. *Dementia and geriatric cognitive disorders*. 2008;25(1):1-8.
188. Smith T, Gildeh N, Holmes C. The Montreal Cognitive Assessment: validity and utility in a memory clinic setting. *The Canadian Journal of Psychiatry*. 2007;52(5):329-32.
189. Piggott MA, Ballard CG, Rowan E, Holmes C, McKeith IG, Jaros E, et al. Selective loss of dopamine D2 receptors in temporal cortex in dementia with Lewy bodies, association with cognitive decline. *Synapse*. 2007;61(11):903-11.
190. Perry VH, Cunningham C, Holmes C. Systemic infections and inflammation affect chronic neurodegeneration. *Nature Reviews Immunology*. 2007;7(2):161-7.
191. McKeith I, O'Brien J, Walker Z, Tatsch K, Booij J, Darcourt J, et al. Sensitivity and specificity of dopamine transporter imaging with ¹²³I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. *The Lancet Neurology*. 2007;6(4):305-13.
192. Kemp PM, Holmes C. Imaging in dementia with Lewy bodies: a review. *Nuclear medicine communications*. 2007;28(7):511-9.
193. Kemp PM, Hoffmann SA, Tossici-Bolt L, Fleming JS, Holmes C. Limitations of the HMPAO SPECT appearances of occipital lobe perfusion in the differential diagnosis of dementia with Lewy bodies. *Nuclear medicine communications*. 2007;28(6):451-6.
194. Howard RJ, Juszcak E, Ballard CG, Bentham P, Brown RG, Bullock R, et al. Donepezil for the treatment of agitation in Alzheimer's disease. *New England Journal of Medicine*. 2007;357(14):1382-92.
195. Howard R, Juszcak E, Ballard C, Bentham P, Brown R, Bullock R, et al. Donepezil in the treatment of agitation in dementia that is unresponsive to a psychological intervention: A randomised placebo-controlled trial (The CALM-AD Trial). *New England Journal of Medicine*. 2007;347:1441-3.
196. Holmes C, Wilkinson D, Dean C, Clare C, El-Okli M, Hensford C, et al. Risperidone and rivastigmine and agitated behaviour in severe Alzheimer's disease: a randomised double blind placebo controlled study. *International journal of geriatric psychiatry*. 2007;22(4):380.
197. Holmes C, McCulley M, Nicoll J, Alder J, Chen C-H, Francis P. Genetic variation in the 5-HT_{2A} receptor and altered neocortical [³H] ketanserin binding in Alzheimer's disease. *Neuroscience letters*. 2007;420(1):58-60.
198. Boche D, Bridges L, Neal J, Wilkinson D, Holmes C, Love S, et al. Variability of A beta removal after A beta 42 immunization in Alzheimer's disease. 2007.
199. Aalten P, Verhey FR, Boziki M, Bullock R, Byrne EJ, Camus V, et al. Neuropsychiatric syndromes in dementia. *Dementia and geriatric cognitive disorders*. 2007;24(6):457-63.
200. Robert PH, Byrne J, Aalten P, Nobili F, deDeyn PP, Bullock R, et al. P1-434: Apathy and depressive symptoms in Alzheimer's disease. Results from the European Alzheimer's Disease Consortium. *Alzheimer's & Dementia*. 2006;2:S225-S.
201. Perry V, Cunningham C, Holmes C. Interaction between systemic inflammation and brain inflammation in chronic neurodegeneration. *Journal of Neurochemistry*. 2006;96(s1):141-2.

202. Nicoll JA, Barton E, Boche D, Neal JW, Ferrer I, Thompson P, et al. A β species removal after A β 42 immunization. *Journal of Neuropathology & Experimental Neurology*. 2006;65(11):1040-8.
203. Holmes C, Knights A, Dean C, Hodkinson S, Hopkins V. Keep music live: music and the alleviation of apathy in dementia subjects. *International Psychogeriatrics*. 2006;18(4):623.
204. Holmes C, editor *Senile plaques*. Library of Congress Cataloging-in-Publication Data; 2006: Wiley Online Library.
205. Holmes C. The molecular pathology of severe dementia. *Severe Dementia*. 2006:33-40.
206. Elliott MS, Abuhamdah S, Huang L, Perry EK, Ballard C, Lees G, et al. P1-435: Essential oils as potential treatment for agitation in severe dementia: Elucidation of the pharmacological mechanism of Melissa and Lavender oils. *Alzheimer's & Dementia*. 2006;2:S225-S.
207. Bridges LR, Boche D, Neal J, Love S, Esiri M, Wilkinson D, et al. Immunization with Abeta42 results in variable clearance of Abeta plaques in Alzheimer's disease. 2006.
208. Bridges L, Boche D, Neal J, Love S, Esiri M, Wilkinson D, et al. IMMUNIZATION WITH ABETA42 RESULTS IN VARIABLE CLEARANCE OF ABETA PLAQUES IN ALZHEIMER'S DISEASE: 177. *Brain Pathology*. 2006;16.
209. Boche D, Holmes C, Perry V, Vlachouli C, Thompson P, Nicoll J. Neuroinflammation and Alzheimer's disease: implications of Abeta immunotherapy. 2006.
210. Boche D, Barton E, Neal J, Ferrer I, Wilkinson D, Bayer A, et al. Effects of Abeta immunotherapy on cerebral amyloid angiopathy in Alzheimer's disease. 2006.
211. Ashton PA, Woolhouse S, Clark S, Hopkins V, Wilkinson D, Holmes C. The effect of link nurses on hospital readmission rates. *Nursing times*. 2006;102(42):34-5.
212. Alexander C, Johannessen A, Anderson J, Johns D, Angst J, Kessler R, et al. Dear Readers As the year draws to an end, we would like to thank you for your continued interest in *Disease Management & Health Outcomes*. We hope that you have found the articles in the journal in 2006 interesting and informative. Our publishing schedule for 2007 is well under way, and we are pleased to be bringing you many more high-quality, authoritative and state-of-the-art articles over the coming year. 2006.
213. Kemp PM, Hoffmann SA, Holmes C, Bolt L, Ward T, Holmes RB, et al. The contribution of statistical parametric mapping in the assessment of precuneal and medial temporal lobe perfusion by 99mTc-HMPAO SPECT in mild Alzheimer's and Lewy body dementia. *Nuclear medicine communications*. 2005;26(12):1099-106.
214. Kemp P, Hoffmann S, Holmes C, Ward A, Bolt L, Fleming J. A8 THE ROLE OF HMPAO IMAGING OF THE PRECUNEUS AND MEDIAL TEMPORAL LOBE IN SUSPECTED ALZHEIMER'S DISEASE. *Nuclear Medicine Communications*. 2005;26(3):273.
215. Holmes C, McCulley MC. Pharmacogenetics and the treatment of Alzheimer's disease. *Practical Old Age Psychopharmacology: A Multi-professional Approach*. 2005:227.
216. Holmes C, Ballard C, Lehmann D, Smith AD, Beaumont H, Day I, et al. Rate of progression of cognitive decline in Alzheimer's disease: effect of butyrylcholinesterase K gene variation. *Journal of Neurology, Neurosurgery & Psychiatry*. 2005;76(5):640-3.
217. Holmes C. Molecular pathology of Alzheimer's disease. *Psychiatry*. 2005;4(1):37-40.
218. Dunn N, Mullee M, Perry VH, Holmes C. Association between dementia and infectious disease: evidence from a case-control study. *Alzheimer Disease & Associated Disorders*. 2005;19(2):91-4.

219. Dunn N, Holmes C, Mullee M. Does lithium therapy protect against the onset of dementia? *Alzheimer Disease & Associated Disorders*. 2005;19(1):20-2.
220. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Reply to "Specificity of mechanisms for plaque removal after A β immunotherapy for Alzheimer disease". *Nature Medicine*. 2004;10(2):118-9.
221. McCulley MC, Day IN, Holmes C. Association between interleukin 1- β promoter (-511) polymorphism and depressive symptoms in Alzheimer's disease. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*. 2004;124(1):50-3.
222. Holmes C, Wilkinson D, Dean C, Vethanayagam S, Olivieri S, Langley A, et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. *Neurology*. 2004;63(2):214-9.
223. Holmes C, Dunn N, Mullee M, Perry H. P2-251 Association between dementia and systemic infectious disease: evidence from a case-control study. *Neurobiology of Aging*. 2004(25):S303-S4.
224. Holmes C, Burns A, Passmore P, Forsyth D, Wilkinson D. AD2000: design and conclusions. *The Lancet*. 2004;364(9441):1213-4.
225. Holmes C, Ballard C. Aromatherapy in dementia. *Advances in psychiatric treatment*. 2004;10(4):296-300.
226. Engelborghs S, Holmes C, McCulley M, De Deyn PP. P4-086 5-HT_{2A} receptor polymorphism may modulate antipsychotic treatment response in Alzheimer's disease. *Neurobiology of Aging*. 2004(25):S498-S9.
227. Engelborghs S, Holmes C, McCulley M, De Deyn PP. 5-HT_{2A} receptor polymorphism may modulate antipsychotic treatment response in Alzheimer's disease. *International journal of geriatric psychiatry*. 2004;19(11):1108-9.
228. Engelborghs S, Holmes C, McCulley M, De Deyn P. 5-HT_{2A} receptor polymorphism may modulate antipsychotic treatment response in Alzheimer's disease: P2003. *European Journal of Neurology Supplement*. 2004;11:183-4.
229. Ballard CG, Jacoby R, Del Ser T, Khan MN, Munoz DG, Holmes C, et al. Neuropathological substrates of psychiatric symptoms in prospectively studied patients with autopsy-confirmed dementia with Lewy bodies. *American Journal of Psychiatry*. 2004;161(5):843-9.
230. Ballard C, Perry E, Lehmann D, Wesnes K, Holmes C. Butyrylcholinesterase: Impact on symptoms and progression of cognitive impairment in dementia. *Neurobiology of Aging*. 2004;25:3.
231. Zhang B, Holmes C, Sanassy S, Day I. A study of UCH-L1 (PGP 9.5 (gene I93M) mutation in British Caucasian dementia patients. *Neuropathology and Applied Neurobiology*. 2003;29(2).
232. Wilkinson D, Holmes C. Re: prophylactic therapy with lithium in elderly patients with Unipolar Major Depression. *International Journal of Geriatric Psychiatry*. 2003;18(4):354-.
233. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid- β peptide: a case report. *Nature medicine*. 2003;9(4):448-52.
234. Nicoll J, Wilkinson D, Holmes C, Weller R. Neuropathology of human Alzheimer's disease following immunization with amyloid β -peptide. *Neuropathology and Applied Neurobiology*. 2003;29(2).
235. Nicoll J, Wilkinson D, Holmes C. First Reports of Adverse Drug Reactions (ADRs) in Recent Weeks. *Rev Esp Cardiol*. 2003;56:215-6.

236. Kemp P, Holmes C, Hoffmann S, Wilkinson S, Zivanovic M, Thom J, et al. A randomised placebo controlled study to assess the effects of cholinergic treatment on muscarinic receptors in Alzheimer's disease. *Journal of Neurology, Neurosurgery & Psychiatry*. 2003;74(11):1567-70.
237. Kemp P, Holmes C, Hoffmann S, Bolt L, Holmes R, Rowden J, et al. Alzheimer's disease: differences in technetium-99m HMPAO SPECT scan findings between early onset and late onset dementia. *Journal of Neurology, Neurosurgery & Psychiatry*. 2003;74(6):715-9.
238. Holmes C, Lovestone S. Long-term cognitive and functional decline in late onset Alzheimer's disease: therapeutic implications. *Age and ageing*. 2003;32(2):200-4.
239. Holmes C, Kemp PM, Hoffmann S, Wilkinson S, Zivanovic M, Thom J, et al., editors. *The Effects of Cholinergic Therapy (Donepezil) in Alzheimer's Disease as Demonstrated by Imaging the Post-Synaptic Muscarinic Receptor*. The Eleventh International Congress; 2003.
240. Holmes C, El-Okl M, Williams A, Cunningham C, Wilcockson D, Perry V. Systemic infection, interleukin 1 β , and cognitive decline in Alzheimer's disease. *Journal of Neurology, Neurosurgery & Psychiatry*. 2003;74(6):788-9.
241. Holmes C, Dean C, Clare C, Vethanayagam S, Olivieri S, Langley A, et al., editors. *The Effects of Donepezil on Behavioral and Psychological Symptoms of Dementia in Patients with Alzheimer's Disease*. The Eleventh International Congress; 2003.
242. Holmes C, Arranz M, Collier D, Powell J, Lovestone S. Depression in Alzheimer's disease: the effect of serotonin receptor gene variation. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*. 2003;119(1):40-3.
243. Holmes C, editor *The Genetics of BPSD*. The Eleventh International Congress; 2003.
244. Holmes C. Neuropathology and genetics of dementia. *International journal of psychiatry in clinical practice*. 2003;7(1):71-3.
245. Zhang B, Holmes C, Day I, Lovestone S, editors. *Ubiquitin carboxyl-terminal hydrolase-L1 gene 193M mutation and dementia*. NEUROBIOLOGY OF AGING; 2002: ELSEVIER SCIENCE INC 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA.
246. Wilkinson D, Holmes C, Woolford J, Stammers S, North J. Prophylactic therapy with lithium in elderly patients with unipolar major depression. *International journal of geriatric psychiatry*. 2002;17(7):619-22.
247. Holmes C, Mann A. Alzheimer's Disease: One or Several? *Principles and Practice of Geriatric Psychiatry*. 2002:307-.
248. Holmes C, Lovestone S, editors. *Long-term cognitive and functional decline in late onset Alzheimer's disease: Therapeutic implications*. NEUROBIOLOGY OF AGING; 2002: ELSEVIER SCIENCE INC 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA.
249. Holmes C, Lovestone S. The clinical phenotype of familial and sporadic late onset Alzheimer's disease. *International journal of geriatric psychiatry*. 2002;17(2):146-9.
250. Holmes C, Hopkins V, Ronenvinge H, Wilkinson D, MacLaughlin V, Hensford C, editors. *The effects of aromatherapy on symptoms of agitation in patients with severe dementing illness*. NEUROBIOLOGY OF AGING; 2002: ELSEVIER SCIENCE INC 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA.
251. Holmes C, Hopkins V, Hensford C, MacLaughlin V, Wilkinson D, Rosenvinge H. Lavender oil as a treatment for agitated behaviour in severe dementia: a placebo controlled study. *International journal of geriatric psychiatry*. 2002;17(4):305-8.
252. Holmes C, El Okl M, Williams A, Perry H, editors. *Systemic inflammation, cytokine production and cognitive decline in Alzheimer's disease: A pilot study*. NEUROBIOLOGY OF

AGING; 2002: ELSEVIER SCIENCE INC 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA.

253. Holmes C, Arranz M, Collier D, Powell J, Lovestone S, editors. Depression in Alzheimer's disease: The effect of serotonin receptor gene variation. NEUROBIOLOGY OF AGING; 2002: ELSEVIER SCIENCE INC 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA.

254. Holmes C. The genetics of Alzheimer's disease. British Menopause Society Journal. 2002;8(1):20-3.

255. Holmes C. Genetics of Down's syndrome and Alzheimer's disease. The British Journal of Psychiatry. 2002;181.

256. Holmes C. Genotype and phenotype in Alzheimer's disease. The British Journal of Psychiatry. 2002;180(2):131-4.

257. Clive GB, Jennifer A, Margaret P, Mary J, Ian M, Holmes C, et al. Disturbances of consciousness in dementia with Lewy bodies associated with alteration in nicotinic receptor binding in the temporal cortex. 2002.

258. Burns A, Byrne J, Ballard C, Holmes C. Sensory stimulation in dementia: an effective option for managing behavioural problems. British Medical Journal Publishing Group; 2002.

259. Ballard C, Johnson M, Piggott M, Perry R, O'Brien J, Rowan E, et al. A positive association between 5HT re-uptake binding sites and depression in dementia with Lewy bodies. Journal of affective disorders. 2002;69(1-3):219-23.

260. Holmes C, Smith H, Ganderton R, Arranz M, Collier D, Powell J, et al. Psychosis and aggression in Alzheimer's disease: the effect of dopamine receptor gene variation. Journal of Neurology, Neurosurgery & Psychiatry. 2001;71(6):777-9.

261. Holmes C. The clinical phenotype and genotype of late onset Alzheimer's disease: King's College London (University of London); 2001.

262. Court J, Ballard C, Piggott M, Johnson M, O'Brien J, Holmes C, et al. Visual hallucinations are associated with lower α bungarotoxin binding in dementia with Lewy bodies. Pharmacology Biochemistry and Behavior. 2001;70(4):571-9.

263. McKeith I, Perry R, O'Brien J, Burn D, Ballard C, Swann A, et al. One year follow-up of parkinsonism in dementia with Lewy bodies. Dementia and Geriatric Cognitive Disorders. 2000.

264. McAuley D, Johnston G, Marra C, Silveri MC, Gainotti G, Ólafsdóttir M, et al. APOE Genotype and Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders. 2000;11(4):237-.

265. Holmes C, Wilkinson D. Molecular biology of Alzheimer's disease. Advances in Psychiatric Treatment. 2000;6(3):193-200.

266. Holmes C. Behavioral and Psychological Symptoms of Dementia (BPSD): A Clinical and Research Update-ETIOLOGY-Contribution of Genetics to the Understanding of Behavioral and Psychological Symptoms of Dementia. International Psychogeriatrics. 2000;12(1):83-8.

267. Holmes C. Contribution of genetics to the understanding of behavioral and psychological symptoms of dementia. International Psychogeriatrics. 2000;12(S1):83.

268. Cairns N, Murray A, Holmes C, Lantos P, editors. Neuropathological correlates of psychotic symptoms in Alzheimer's disease. BRAIN PATHOLOGY; 2000: INT SOC NEUROPATHOLOGY 200 LOTHROP ST A506, PITTSBURGH, PA 15213 USA.

269. Ballard C, Piggott M, Johnson M, Cairns N, Perry R, McKeith I, et al. Delusions associated with elevated muscarinic binding in dementia with Lewy bodies. Annals of neurology. 2000;48(6):868-76.

270. Ballard C, O'Brien J, Swann A, Neill D, Lantos P, Holmes C, et al. One year follow-up of parkinsonism in dementia with Lewy bodies. *Dementia and geriatric cognitive disorders*. 2000;11(4):219-22.